Aptose Biosciences, Inc. (NASDAQ: APTO) Starts Presentation at 29th Annual ROTH Conference
Aptose Biosciences (NASDAQ: APTO) is a clinical-stage biotechnology company committed to discovering and developing personalized therapies addressing unmet medical needs in oncology. Aptose is advancing new therapeutics focused on novel cellular targets on the leading edge of cancer research coupled with companion diagnostics to identify the optimal patient population for its products. The company's small molecule cancer therapeutics pipeline includes products designed to provide single agent efficacy and to enhance the efficacy of other anti-cancer therapies and regimens without overlapping toxicities. For more information, visit the company’s website at www.aptose.com. About NetworkNewsWire NetworkNewsWire (NNW) provides news aggregation and syndication, enhanced press…
